The short version.
Growth hormone is genuinely lipolytic. It stimulates hormone-sensitive lipase activity, mobilizes free fatty acids, and shifts substrate use toward fat oxidation. That biology is the basis for the body-composition language around sermorelin.
What sermorelin actually does: it restores GHRH signaling, supporting the body's own pulsatile GH release. It doesn't deliver supraphysiologic GH, and it doesn't override metabolic fundamentals. The framing matters — this is body recomposition (less fat mass, preserved lean mass), not weight loss in the GLP-1 sense.
What the literature actually says.
GHRH-analog studies in older adults consistently show modest body-composition shifts: small reductions in fat mass, modest increases in lean mass, IGF-1 within physiologic range. Effect sizes aren't dramatic — typical published changes are in the low single-digit percentage range over months — but they're directionally consistent.
What sermorelin doesn't do: produce GLP-1-magnitude weight loss. Patients who want a primary weight-loss intervention are usually better served by FDA-approved options. Sermorelin's role in body composition is as a slow, supportive tool — most useful alongside training, protein-forward eating, and adequate sleep.
The honest framing: sermorelin is reasonable as a body-composition adjunct in adults with documented GH decline. It's not a fat-loss drug. The marketing that pushes it that way oversells what GHRH-analog effect sizes actually look like.
Sermorelin is body composition, not weight loss. The marketing that conflates the two oversells what GHRH analogs actually do.
Why oversight matters.
The internet sells almost any peptide as research chemicals — vials with disclaimers, no prescription, no provider, no follow-up. The risk isn't theoretical. Sterility, peptide identity, peptide content, and contamination all vary widely between gray-market vendors. The FDA has been explicit that compounded drugs aren't FDA-approved, and that research-only labels don't protect consumers when products end up in human use.
Oversight isn't a bureaucratic checkbox. It's a U.S.-licensed prescriber who reviews your history before prescribing, a 503A compounding pharmacy that sources active pharmaceutical ingredient and prepares the medication under USP 797 sterile standards, and a follow-up cadence that lets someone catch a problem before it becomes a worse one.
How Boswell handles this.
Boswell pairs you with a U.S.-licensed physician for the intake. They review your goals, medications, history, and any contraindications before prescribing. If a protocol isn't appropriate, you don't get it. If it is, the prescription goes to a 503A compounding pharmacy that prepares the medication under sterile compounding standards, labels it for you specifically, and ships it directly.
Refills aren't automatic — they involve a check-in. The point isn't to gate access; it's to keep someone clinical in the loop while you're on therapy. How Boswell works →
Questions worth asking your provider.
- If primary weight loss is the goal, are FDA-approved options on the table first?
- What's the realistic body-composition expectation over 12-24 weeks?
- How does sermorelin fit alongside training and nutrition — not instead of?
- Should we track DEXA or bioimpedance to objectively measure recomposition?
- Does CJC-1295 + ipamorelin better fit my goals?
Sources